254 related articles for article (PubMed ID: 31833974)
1. Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies.
Erickson BK; Zeybek B; Santin AD; Fader AN
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):57-64. PubMed ID: 31833974
[TBL] [Abstract][Full Text] [Related]
2. HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand.
Buza N
Arch Pathol Lab Med; 2021 Jun; 145(6):687-691. PubMed ID: 32649220
[TBL] [Abstract][Full Text] [Related]
3. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Fader AN; Roque DM; Siegel E; Buza N; Hui P; Abdelghany O; Chambers SK; Secord AA; Havrilesky L; O'Malley DM; Backes F; Nevadunsky N; Edraki B; Pikaart D; Lowery W; ElSahwi KS; Celano P; Bellone S; Azodi M; Litkouhi B; Ratner E; Silasi DA; Schwartz PE; Santin AD
J Clin Oncol; 2018 Jul; 36(20):2044-2051. PubMed ID: 29584549
[TBL] [Abstract][Full Text] [Related]
4. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
Groeneweg JW; Hernandez SF; Byron VF; DiGloria CM; Lopez H; Scialabba V; Kim M; Zhang L; Borger DR; Tambouret R; Foster R; Rueda BR; Growdon WB
Clin Cancer Res; 2014 Dec; 20(24):6517-6528. PubMed ID: 25294905
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy in the treatment of uterine serous carcinoma.
Schwab CL; Santin AD
Pharmacogenomics; 2015 Jan; 16(2):97-9. PubMed ID: 25616096
[No Abstract] [Full Text] [Related]
6. Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it.
Menderes G; Lopez S; Han C; Altwerger G; Gysler S; Varughese J; Schwartz PE; Santin AD
Discov Med; 2018 Aug; 26(141):39-50. PubMed ID: 30265854
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Black JD; Lopez S; Cocco E; Bellone S; Altwerger G; Schwab CL; English DP; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Br J Cancer; 2015 Sep; 113(7):1020-6. PubMed ID: 26325104
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
Batman S; Bohn J; Weisenberger MW; Hersh A; Bruegl A; Caughey A; Winter W
Gynecol Oncol; 2021 Jan; 160(1):214-218. PubMed ID: 33393480
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.
Tymon-Rosario J; Siegel ER; Bellone S; Harold J; Adjei N; Zeybek B; Mauricio D; Altwerger G; Menderes G; Ratner E; Clark M; Andikyan V; Huang GS; Azodi M; Schwartz PE; Fader AN; Santin AD
Gynecol Oncol; 2021 Oct; 163(1):93-99. PubMed ID: 34372971
[TBL] [Abstract][Full Text] [Related]
10. Targeting HER2 in ovarian and uterine cancers: challenges and future directions.
Teplinsky E; Muggia F
Gynecol Oncol; 2014 Nov; 135(2):364-70. PubMed ID: 25220628
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial).
Takahashi K; Ishibashi E; Kubo T; Harada Y; Hayashi H; Kano M; Shimizu Y; Shirota H; Mori Y; Muto M; Ishioka C; Dosaka-Akita H; Matsubara H; Nishihara H; Sueoka-Aragane N; Toyooka S; Hirakawa A; Tateishi U; Miyake S; Ikeda S
Medicine (Baltimore); 2020 Aug; 99(32):e21457. PubMed ID: 32769873
[TBL] [Abstract][Full Text] [Related]
12. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy.
Rottmann D; Snir OL; Wu X; Wong S; Hui P; Santin AD; Buza N
Mod Pathol; 2020 Jan; 33(1):118-127. PubMed ID: 31477811
[TBL] [Abstract][Full Text] [Related]
13. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Roviello G; Aprile G; D'Angelo A; Iannone LF; Roviello F; Polom K; Mini E; Catalano M
Gastric Cancer; 2021 Jul; 24(4):765-779. PubMed ID: 33742317
[TBL] [Abstract][Full Text] [Related]
14. HER2 in uterine serous carcinoma: Current state and clinical perspectives.
Navarro Sanchez JM; Finkelman BS; Turner BM; Katerji H; Wang X; Varghese S; Wang T; Peng Y; Hicks DG; Zhang H
Am J Clin Pathol; 2023 Oct; 160(4):341-351. PubMed ID: 37267036
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
Bookman MA; Darcy KM; Clarke-Pearson D; Boothby RA; Horowitz IR
J Clin Oncol; 2003 Jan; 21(2):283-90. PubMed ID: 12525520
[TBL] [Abstract][Full Text] [Related]
16. Advances in Human Epidermal Growth Factor Receptor 2-Targeted Therapy in Upper Gastrointestinal Cancers.
Lee J; Ku G
Hematol Oncol Clin North Am; 2024 Jun; 38(3):585-598. PubMed ID: 38521686
[TBL] [Abstract][Full Text] [Related]
17. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.
Erickson BK; Najjar O; Damast S; Blakaj A; Tymon-Rosario J; Shahi M; Santin A; Klein M; Dolan M; Cimino-Mathews A; Buza N; Ferriss JS; Stone RL; Khalifa M; Fader AN
Gynecol Oncol; 2020 Oct; 159(1):17-22. PubMed ID: 32709539
[TBL] [Abstract][Full Text] [Related]
18. HER2 Protein Overexpression and Gene Amplification in Tubo-Ovarian High-grade Serous Carcinomas.
Ersoy E; Cao QJ; Otis CN
Int J Gynecol Pathol; 2022 Jul; 41(4):313-319. PubMed ID: 34320531
[TBL] [Abstract][Full Text] [Related]
19. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]